Drug Profile
SKL N09
Alternative Names: SKL-N09Latest Information Update: 28 Oct 2019
Price :
$50
*
At a glance
- Originator SK biopharmaceuticals
- Class Antiepileptic drugs
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Epilepsy
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for phase-I development in Epilepsy in USA
- 22 Aug 2017 SK Biopharmaceuticals is planning a phase II trial for Epilepsy (SK biopharmaceuticals website, August 2017)